TV 2252

Drug Profile

TV 2252

Latest Information Update: 23 Feb 2004

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myasthenia gravis

Most Recent Events

  • 23 Feb 2004 Discontinued - Preclinical for Myasthenia gravis in Israel (unspecified route)
  • 22 Aug 2001 No-Development-Reported for Myasthenia gravis in Israel (Unknown route)
  • 08 Jun 1998 Preclinical development for Myasthenia gravis in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top